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Abstract
Background: Contrast-induced nephropathy is a common complication of contrast administration in patients with
chronic kidney disease and diabetes. Its pathophysiology is not well understood; similarly the role of intravenous or
oral acetylcysteine is unclear. Randomized controlled trials to date have been conducted without detailed
knowledge of the effect of acetylcysteine on renal function. We are conducting a detailed mechanistic study of
acetylcysteine on normal and impaired kidneys, both with and without contrast. This information would guide the
choice of dose, route, and appropriate outcome measure for future clinical trials in patients with chronic kidney
disease.
Methods/Design: We designed a 4-part study. We have set up randomised controlled cross-over studies to assess
the effect of intravenous (50 mg/kg/hr for 2 hrs before contrast exposure, then 20 mg/kg/hr for 5 hrs) or oral
acetylcysteine (1200 mg twice daily for 2 days, starting the day before contrast exposure) on renal function in
normal and diseased kidneys, and normal kidneys exposed to contrast. We have also set up a parallel-group
randomized controlled trial to assess the effect of intravenous or oral acetylcysteine on patients with chronic
kidney disease stage III undergoing elective coronary angiography. The primary outcome is change in renal blood
flow; secondary outcomes include change in glomerular filtration rate, tubular function, urinary proteins, and
oxidative balance.
Discussion: Contrast-induced nephropathy represents a significant source of hospital morbidity and mortality. Over
the last ten years, acetylcysteine has been administered prior to contrast to reduce the risk of contrast-induced
nephropathy. Randomized controlled trials, however, have not reliably demonstrated renoprotection; a recent large
randomized controlled trial assessing a dose of oral acetylcysteine selected without mechanistic insight did not
reduce the incidence of contrast-induced nephropathy. Our study should reveal the mechanism of effect of
acetylcysteine on renal function and identify an appropriate route for future dose response studies and in time
randomized controlled trials.
Trial registration: Clinical Trials.gov: NCT00558142; EudraCT: 2006-003509-18.
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Radiographic contrast material has been used for over
70 years to enhance medical imaging in diagnostic and
interventional procedures. While considered generally
safe in healthy patients [1,2], it can lead to renal impair-
ment particularly in the presence of co-morbidity [3].
Contrast-induced nephropathy (CIN) is typically defined
as an increase in serum creatinine of 25% over baseline,
or an absolute increase of 0.5 mg/dL (44.2 μmol/l),
within 48 hours of contrast administration [1]. Although
usually reversible, renal replacement therapy may be
required in a small number of patients.
Contrast-induced nephropathy occurs in less than 2%
of patients with normal renal function, but in up to 50%
of those with pre-existing renal impairment and diabetes
[1]. Other risk factors include congestive cardiac failure,
age over 70 years, dehydration, and concurrent adminis-
tration of nephrotoxic drugs [4,5]. With increasing utili-
sation of contrast during investigations such as coronary
angiography, particularly in an ageing population with
multiple co-morbidities, CIN has become a significant
source of hospital morbidity and mortality [1,2,6]. Not
only has it been reported as the third most common
cause of in-hospital acute renal failure [7], patients with
chronic kidney disease (CKD) who develop CIN follow-
ing PCI demonstrate a 3-fold increase in hospital mor-
tality compared to those without CIN (14.9% vs 4.9% in
one study) [8].
Mechanism
Injury to the renal medulla appears to be the primary
problem in CIN, although the precise mechanisms
involved are not well understood. Current hypotheses
include disturbances in renal haemodynamics, an osmo-
tic effect, and a direct toxic effect of contrast media on
tubular epithelial cells [1,9,10]. The last of these may be
a result of toxic free radical release occurring after con-
trast administration. Whether these mechanisms act
separately or together to cause renal insufficiency is not
clear. Administration of contrast leads to a biphasic hae-
modynamic change in the kidney, with an initial transi-
ent increase followed by a prolonged decrease in renal
blood flow (RBF) [9]. Current prevention strategies
therefore aim at maintaining urine flow and reducing
oxidative stress [11]. This may be achieved through the
use of intravenous fluids, a low dose of iso-osmolar con-
trast, withholding nephrotoxic drugs, and perhaps acet-
ylcysteine via its vasodilatory and antioxidative
properties [4].
Despite a paucity of randomised controlled trial (RCT)
data, intravenous hydration pre- and post-contrast is
widely accepted as beneficial in counteracting the effects
of contrast through augmenting RBF and glomerular fil-
tration rate (GFR) [4,6]. Hydration regimens are
generally based on administration of ~1 mL/kg per
hour, commencing 6-12 hours pre-contrast and continu-
ing for 12 hours post-contrast [6,12,13]. While sodium
chloride is most commonly recommended, sodium
bicarbonate might further reduce the risk of CIN [14].
Such regimens, however, are not practicable in the out-
patient setting.
Contrast agents are classified according to osmolality.
This is important as agents with greater osmolality are
more nephrotoxic [4]. First generation hyperosmolar
(1500 - 1800 mOsm/kg) agents have gradually been
replaced by low-osmolar (600 - 850 mOsm/kg), and
subsequently, iso-osmolar (280 mOsm/kg) agents, both
of which cause less CIN than first generation agents [4].
Any additional benefit offered by iso-osmolar over low-
osmolar agents, however, is less clear [15-18]. In an
RCT of 129 patients, Aspelin et al. [19] reported a sig-
nificantly reduced incidence of CIN associated with the
use of the iso-osmolar agent iodixanol compared to the
low-osmolar agent iohexol [19]. However, this study did
not control for the volume of contrast administered, an
independent predictor for the development of CIN
[20,21]. A more recent RCT reported no significant dif-
ference in the incidence of nephrotoxicity associated
with iso- and low-osmolar agents [22].
The role of acetylcysteine
Acetylcysteine is commonly given before contrast media
in patients with renal impairment in an effort to mini-
mise the risk of CIN. Use of this agent is attractive due
to its wide availability, ease of administration, and low
cost. However, despite extensive research, any benefit
offered by acetylcysteine remains unclear. In fact, a CIN
Consensus Working Panel reported in 2006 that “no
adjunctive medical or mechanical treatment has been
proved to be efficacious in reducing the risk of CIN”,
and specifically that “N-acetylcysteine is not consistently
effective in reducing the risk for CIN” [11].
A systematic review called for a large multi-centre
RCT to be conducted to address this research question
[23]. However, RCTs to date have been conducted with-
out detailed knowledge of the effect of acetylcysteine on
renal function that would have guided the choice of out-
come measure or regimen. A variety of doses (from
around 7 to 200 mg/kg total doses) and routes of
administration have also been used [23]. Therefore,
there is first a need for a detailed mechanistic study of
acetylcysteine use in patients with chronic kidney dis-
ease receiving contrast medium [24]. Such a study
should inform any decisions regarding the most appro-
priate dose and route of administration of acetylcysteine.
Acetylcysteine possesses both vasodilatory [25] and
antioxidative [4] properties and may be renoprotective
via these mechanisms. Previous studies have assessed
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administration. Serum creatinine, however, is not only
an insensitive marker of altered renal function [26], but
acetylcysteine itself may cause a reduction in serum
creatinine independent of GFR [27]. Furthermore, if
acetylcysteine offers renoprotection via vasodilatation,
serum creatinine would not be the most appropriate
marker. Finally, as highlighted in previous studies that
have used a variety of doses (from around 7 to 200 mg/
kg total doses) and routes of administration, the opti-
mum dose and route of administration is not yet known
[23].
We hypothesized that acetylcysteine may exert a reno-
protective effect in CIN by a mechanism involving renal
vasodilatation and/or its potential role as an antioxidant.
To investigate this we took a structured 4-part approach
to the question, using randomized controlled crossover
studies to assess the effect of acetylcysteine on renal
function in both normal and diseased kidneys, and the
effect of contrast on normal kidneys, with and without
acetylcysteine treatment. We also designed a parallel-
group randomized controlled trial of patients with CKD
stage III undergoing elective coronary angiography with
and without acetylcysteine treatment. We believe this
mechanistic study will enable us to control variables and
interpret any role acetylcysteine plays in preventing CIN
in CKD patients.
Methods/Design
Study design
The study is being performed simultaneously in four
groups of participants (Figure 1). The local research
ethics committee approved the protocol and written
informed consent is attained from each participant
before entering the study. Studies 1-3 are randomised,
placebo-controlled, three-way, crossover human volun-
teer studies of eight participants. All studies are per-
formed at the Wellcome Trust Clinical Research
Facility, Royal Infirmary of Edinburgh.
Study 1 investigates healthy volunteers receiving oral
acetylcysteine, intravenous (IV) acetylcysteine, or pla-
cebo; study 2 patients with CKD stage III receiving oral
acetylcysteine, IV acetylcysteine, or placebo; and study 3
healthy volunteers receiving IV contrast plus either oral
acetylcysteine, IV acetylcysteine, or placebo. Participants
are randomised to receive all three treatments on three
different occasions.
Study 4 is a randomised, placebo-controlled, three-way
parallel group study in patients undergoing elective cor-
onary angiography with sufficient studies being per-
formed to obtain 66 completed studies. Participants in
this study are randomised to one arm only, receiving
oral acetylcysteine, IV acetylcysteine, or placebo.
Participants are followed up at 24 hrs and 72 hrs after
acetylcysteine administration.
We are studying healthy volunteers in order to iden-
tify the effects of acetylcysteine and contrast on healthy
kidneys. This should provide us with data to help inter-
pret the studies in CKD patients. In addition, while
healthy patients rarely get CIN after contrast adminis-
tration, the currently used marker of CIN (raised serum
creatinine) is a crude measure of renal dysfunction since
GFR will only fall after RBF has been substantially
reduced for a long period of time. It is likely that small
sub-clinical changes will occur in healthy patients that
will help illustrate how contrast and acetylcysteine affect
the kidney [28]. Any changes in renal function that
occur in the volunteers are expected to be transient.
 
 
 
 
 
 
 
 
 
 
 
 
 
Study 1 
8 volunteers 
Crossover study 
Study 2 
8 volunteers 
Crossover study 
Study 3 
8 volunteers 
Crossover study 
Study 4 
66 volunteers 
Parallel study 
NORMAL KIDNEY 
FUNCTION
CKD STAGE III 
NO CONTRAST 
IV CONTRAST 
Figure 1 4 way study design.
Sandilands et al. BMC Clinical Pharmacology 2012, 12:3
http://www.biomedcentral.com/1472-6904/12/3
Page 3 of 8Subjects
All participants are non-smoking, male volunteers aged
over 45 years with a body mass index (BMI) of 22-40
kg/m
2. Exclusion criteria for studies 1 and 3 include
clinically significant co-morbidity (heart failure, hyper-
tension, diabetes mellitus, coagulopathy); thyroid disease,
asthma, atopy or myasthenia gravis; a history of allergy
or sensitivity to acetylcysteine or contrast medium; cur-
rent intake of prescription medicines; and a blood dona-
tion within the last 3 months. The same exclusion
criteria applied for studies 2 and 4 except that patients
with CKD stage III can have co-morbidity and take any
prescription medicine with the exception of metformin.
Metformin must be stopped on the day of the procedure
and for two days following.
Our study is restricted to male volunteers. Previous
experience has shown that regular voiding by female
participants while receiving multiple infusions is difficult
while maintaining volunteer privacy. Despite including
only males, we do not know of any reason why the
results will not be as relevant for women as they will be
for men.
Participants can be withdrawn from the trial at their
own request, at the request of the investigator in the
context of safety concerns, or if the mean arterial pres-
sure or heart rate increased by > 30 mmHg or > 30
bpm, respectively.
Trial interventions
Acetylcysteine
There are currently no data to guide choice of an opti-
mum oral or IV acetylcysteine regimen. This study will
assess the effects of an IV and an oral dose of acetylcys-
teine (IV 200 mg/kg; oral 68.6 mg/kg in a 70 kg patient)
that are similar to those currently used in clinical prac-
tice for the prevention of CIN. The oral dose is expected
to produce a plasma concentration lower than the IV
dose; however, a first pass effect after oral administra-
tion may allow effective conversion in the liver of acetyl-
cysteine into cysteine and then glutathione, increasing
the efficacy of the oral dose [29].
Selection of IV acetylcysteine dose
IV regimens have been assessed for prevention of CIN
since they might be effective when started on the same
day as contrast administration, rather than the day
before [30]. The first trial used a dose similar to that
used for early treatment of paracetamol-induced hepato-
toxicity - 150 mg/kg over 30 min, then 50 mg/kg over 4
hrs (total dose 200 mg/kg) - and reported less nephro-
pathy [10]. Other studies used lower doses (e.g. 500 mg
over 15 mins [7.1 mg/kg in 70 kg patient] or 1000 mg
twice, before and after the procedure, [28.5 mg/kg in 70
kg patient]) and did not find any benefit [30]. Overall,
the choice of acetylcysteine regimen for previous studies
seems to have been based on ease and prior practice in
paracetamol poisoning rather than knowledge of acetyl-
cysteine’s effects on the kidney.
We chose a revised IV high dose regimen (Figure 2)
derived from pharmacokinetic data published by Pre-
scott [31] after Monte Carlo simulations (Dr R Tha-
nacoody, Royal Victoria Infirmary, Newcastle,
unpublished) for two reasons. Firstly, the RCT that
showed benefit with IV acetylcysteine used a high dose
regimen similar to that used for paracetamol poisoning
[23]. The subsequent negative studies used much lower
doses, suggesting that IV acetylcysteine may need to be
given in high doses. Secondly, the high peak plasma
concentration that results from the rapid initial infusion
of acetylcysteine for paracetamol poisoning produces
nausea in about 40% of patients and anaphylactoid reac-
tions in about 20% [32]. Although these reactions are
routine and normally easily and safely treated by stop-
ping the acetylcysteine infusion and administering antie-
metic and antihistamine medications, it was important
to reduce the rate of such reactions in study partici-
pants. The revised regimen provides a similar amount of
acetylcysteine but administers it more evenly across 7
hours, producing a lower peak acetylcysteine concentra-
tion and a lower likelihood of nausea and anaphylactoid
reactions.
The study uses the intravenous acetylcysteine prepara-
tion currently used in the Royal Infirmary of Edinburgh
(Aurum Pharmaceuticals Ltd, Romford, UK) diluted in
5% dextrose solution. Placebo is 5% dextrose solution
for infusion used in the Royal Infirmary of Edinburgh.
Active or placebo infusions are prepared on each study
day by clinical research facility nurses according to the
randomized allocation order.
Selection of oral acetylcysteine dose
The dose used in oral regimens of acetylcysteine has
ranged from 600 mg twice daily for 2 days, starting the
day before radiocontrast administration (total dose 2.4 g,
34.3 mg/kg in a 70 kg patient) [23] up to 1500 mg twice
daily for 2 days (total dose 6 g, 85.7 mg/kg in a 70 kg
patient) [23]. Similar to more recent studies [12,13], we
used 1200 mg (Figure 2) since there is some evidence
that it is more effective than the more usually adminis-
tered 600 mg [23].
Hard gelatin capsules containing acetylcysteine 600
mg or matched placebo (Lactose PhEur 600 mg) are
prepared by Tayside Pharmaceuticals, Dundee (MA
[IMP] #17859), and packaged in participant packs of 8
capsules. The capsules are delivered to the hospital
pharmacy and supplied to participants according to the
randomized allocation order. The active material and
placebo capsule shells and raw material powders are
obtained from an approved GMP supplier with appro-
priate TSE certificates. Capsules are filled by hand.
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ance of contents, and product identification.
Contrast media
Participants in study 3 receive a single IV 100 ml dose
of Visipaque 320 (iodixanol, equivalent to 320 mg
iodine/ml), an iso-osmolar non-ionic radio-contrast
agent, via a peripheral cannula [2]. We chose this dose
because 100 mL is routinely used in the Royal Infirmary
of Edinburgh for coronary angiography in CKD patients
(Radiology Dept, personal communication). Larger doses
of up to 400 mL are used if angioplasty is subsequently
required. Such doses fall within the doses recommended
in the summary of product characteristics [33], Martin-
dale [34], and the literature [15]. The safety profile of
such doses in healthy adults is excellent. In patients
with CKD, iodixanol is at least as safe as other contrast
agents [2]. Recent work suggests that neither CIN nor
oliguria/need for dialysis will occur after administration
of 100 mL of contrast to healthy participants with an
eGFR of > 25.6 mL/min or > 64 mL/min, respectively
[35].
Participants in study 4 received doses of Visipaque
320 as required by the consultant cardiologist doing the
procedure to adequately visualise the coronary arteries
and perform any procedure judged to be necessary.
Study outcome measures
The primary outcome is a change in renal blood flow
(RBF). Secondary outcomes include changes in GFR,
tubular function, urinary proteins, and oxidative balance.
Changes in RBF after acetylcysteine and/or contrast
administration are assessed by measuring plasma para-
aminohippuric acid (PAH) clearance [36]. Change in
RBF is the primary outcome since we expect this mea-
sure to be most sensitive to the effects of acetylcysteine
and/or contrast administration. GFR is the best marker
of global renal function. It can be directly measured
using the
51Cr-EDTA method but this is a complicated
technique and therefore we are using an alternative
method by measuring plasma clearance of inulin [36].
Creatinine and cystatin C are measured in each parti-
cipant. Plasma creatinine is measured by the hospital’s
clinical laboratory using validated methods. Urinary
creatinine is measured by the picric acid method using a
commercial kit (Alpha Laboratories, Ref 17609) in a 96-
well plate. To 20 μL volumes of sample or standard
solutions, 100 μL of Reagents 1 and 2 are added sequen-
tially and the absorbance is measured at 510 nm on a
plate reader immediately and after a further 6 min. The
difference in absorbance values (6 min - 0 min) is used
to calculate the results. Calibration is linear over the
range 0-400 μg/mL of creatinine and samples are diluted
with water as necessary to bring them within this range.
Serum cystatin C concentration may be a better mar-
ker of GFR than creatinine [37]. It is a small cysteine
protease that is secreted at a fixed rate by all nucleated
cells and is not affected by diet or muscle mass. In CIN,
serum cystatin concentration peaks and normalizes
more rapidly than creatinine [38]. Cystatin C is mea-
sured using a standard sandwich enzyme immunoassay
(BioVendor Ref RD191009100) following manufacturers
instructions. Plasma and urine samples are both diluted
1/400 before assay.
Kidney injury molecule-1 (KIM-1) and neutrophil
gelatinase-associated lipocalin (NGAL) are measured in
the urine of each participant. KIM-1 is a type I cell-
membrane glycoprotein containing a unique six-cysteine
immunoglobulin-like domain and mucin domain in its
extracelluclar region [39]. Urinary KIM-1 has been
shown to be an earlier diagnostic indicator of kidney
injury when compared to conventional biomarkers such
as creatinine [39]. NGAL is a protein bound to gelati-
nase in specific granules of neutrophils whose synthesis
may be induced in epithelial cells in the setting of
inflammation [40]. Animal [41] and human [42] studies
have suggested that NGAL may also be powerful early
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Page 5 of 8biomarker of acute kidney injury. KIM-1 and NGAL are
assayed using kits from R&D Systems (Cat N°.s DY1750
and DY1757 respectively) following the manufacturer’s
instructions with calibration ranges of 0-2500 pg/mL.
Urine is assayed undiluted for KIM-1 and diluted 1 in
20 with water for NGAL.
Renal tubular function is assessed by measuring the
kidney’s fractional excretion of sodium [37,43]. Reduc-
tions in fractional excretion will supply information on
renal perfusion and tubular function, and have been
noted previously in CIN [44].
We are measuring plasma acetylcysteine and periph-
eral blood cell glutathione. Plasma aliquots are analysed
by HPLC-FLD using an established method; briefly,
samples are reduced with tributylphosphine, prior to
protein precipitation using trichloroacetic and derivati-
zation with 7-fluoro-benzo-2-oxa-1,3-diazole-4-sulfonate
[45]. Derivatized samples are injected onto a C18 col-
umn (Gemini-NX) and eluted with 100 mM potassium
phosphate:acetonitrile (94:6) at a flow rate of 1 mL/min
prior to fluorescence detection (lex/lem = 385/515
nm). Peak areas are measured for quantitative
calculations.
To quantify the thiol content in the buffy coat, 20 μL
lysis buffer is added to 180 μL buffy coat samples and
incubated at 4°C for 30 min, vortexing every 10 min.
Albumin is removed from the buffy coat sample using
an AlbuminOUT™ kit (G-Biosciences, St Louis, MO,
USA). Protein content of the eluate is measured colori-
metrically with an absorbance of 595 nm using the
Bradford protein assay [46,47]. Samples are then ana-
lysed for thiol content using the same protocol as
described above for plasma samples.
Statistical analysis
Change in RBF is the primary outcome of the study.
Mean RBF in healthy volunteers is 601 mL/min with a
standard deviation of 114 mL/min [48]. A previous
study [48] found the mean RBF in patients with CKD
stage III to be 352 mL/min with a standard deviation of
104 mL/min. The cross-over studies, therefore, have an
80% power (alpha of 0.05) with n = 8 subjects to show a
16% change in RBF in healthy subjects and 33% change
in patients with CKD.
T h ep a r a l l e lg r o u ps t u d yh a sa9 0 %p o w e r( a l p h ao f
0.05) with n = 22 subjects to show a 30% change in RBF
in patients with CKD. Comparisons will be tested via a
Student’s t-test after ANOVA. Statistical significance
will be taken at 5%.
Ethics
Ethics approval was received from the Scotland A
Research Ethics Committee, UK (reference number 07/
MRE00/64).
Discussion
Contrast agents are widely used for angiography and CT
imaging. However, they are also associated with CIN, an
important source of hospital morbidity and mortality.
Although a number of preventative measures aimed at
minimizing risk have been proposed, success has been
partial due in part to the complex and poorly under-
stood pathophysiology of CIN. Since the first clinical
trial assessing acetylcysteine in the prevention of CIN
was published in 2000 [49], there has been much debate
over the degree of renoprotection offered by this drug
[3,4,11,30].
While the use of acetylcysteine may be attractive due
to ease of availability, familiarity of use amongst clini-
cians, and favourable side effect profile, the precise
mechanism of action and appropriate dose and route of
administration remain unclear. This has important
implications for clinical practice as some clinicians
informally report administering greater volumes of con-
trast media to those patients who have received acetyl-
cysteine, in the belief that CIN will be prevented. This
mechanistic trial should not only improve our under-
standing of CIN but may also lead to further dose
response studies and clinical trials.
After initiating our study, two major meta-analyses
were published that came to opposing views about the
efficacy of acetylcysteine in CIN [50,51]. Furthermore, a
recent large Brasilian RCT - ACT Acetylcysteine for con-
trast-induced nephropathy - reported that acetylcysteine
1200 mg oral twice daily for two days, starting the day
before angiography, had no beneficial effect [12]. As a
result, interest in acetylcysteine as a preventative treat-
ment for CIN has fallen. However, like many previous
studies, this study used a dose and route that was based
on the original study [49] and not on any rational scien-
tific basis. It therefore should not be used to discard
acetylcysteine completely as a therapeutic option, in par-
ticular since one positive study used a much higher IV
dose, similar to that administered to patients in one arm
of our study. The results of our study may in fact show
that IV, and not oral, acetylcysteine is required to have
any effect on renal function.
Conducting a trial of this size with volunteers is com-
plex and time consuming - there are over 132 study
days lasting from 07.00 until early evening, together
with 264 follow up visits. Shortly after commencing the
study, the Scottish government introduced a directive to
reduce waiting times for elective coronary angiography.
Simultaneously, our hospital expanded its existing pilot
primary angiography into a regional tertiary referral ser-
vice for patients in three surrounding counties. As a
result, there was a marked fall in the number of elective
coronary angiographies taking place, as more patients
underwent primary procedures. The elective coronary
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potential volunteers for study 4 and so recruitment to
study 4 was, and has remained, significantly slower than
originally anticipated. We were unable to recruit
patients undergoing primary angiographies due to the
time needed for completion of the screening and con-
sent process before the procedure. Only patients under-
going elective procedures were able to start oral
acetylcysteine or placebo tablets 24 hours prior to their
angiography. As a result, the study has taken many
more months than initially anticipated.
We faced further difficulties obtaining PAH and inulin
half way through the study, despite their use worldwide
for many years as a standard method for assessing RBF
and GFR. Since they are not medicines, and are not
licensed for human use, we obtained them directly from
the manufacturers. After commencing the trial, our
sponsor deemed that these compounds had to be
imported via an official importer rather than directly
from the manufacturer. Due to importation regulations,
obtaining permission for import was challenging, leading
to a nine month delay in obtaining these compounds.
Throughout this time, the study was put on hold.
Interest in the use of acetylcysteine to prevent CIN
has fallen since the results of the ACT trial were
announced. However, we believe that it is premature to
discard this affordable, safe, and widely available medi-
cine based on a lack of studies addressing the mechan-
isms of its effect, the best route of administration, and
the correct dose. We hope that our study will ultimately
a l l o wt h ed e s i g no fal a r g ep h a s eI I Is t u d yo fN A Ci n
CIN that uses a rational dose of NAC, given by the cor-
rect route, and assessed using the correct outcome
measure.
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